CV Sciences, Inc. (CVSI): Net Income
-$958.0K
Year ended 2025-12-31
-$2.01M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$958.0K | n/m | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | -$2.39M | n/m | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $3.10M | n/m | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | -$8.21M | n/m | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | -$15.55M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$22.28M | n/m | 2022-04-04, From 2020-01-01 |
| 2019-12-31 | -$16.61M | n/m | 2021-03-19, From 2019-01-01 |
| 2018-12-31 | $10.00M | n/m | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | -$4.90M | n/m | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | -$14.14M | n/m | 2018-03-30, From 2016-01-01 |
| 2015-12-31 | -$12.23M | n/m | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | -$1.31M | n/m | 2016-04-14, From 2014-01-01 |
| 2013-12-31 | -$2.30M | n/m | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | -$45.6K | n/m | 2014-03-28, From 2012-01-01 |
| 2011-12-31 | -$90.2K | n/a | 2013-04-16, From 2011-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| CV Sciences, Inc. (CVSI) | 2025-12-31 | -$958.0K | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$79.62M | n/m |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | -$33.50M | n/m |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | -$49.59M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$124.02M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$68.87M | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$7.49M | n/m |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | -$99.50M | n/m |
| uniQure N.V. (QURE) | 2025-12-31 | -$198.97M | n/m |
Compare CVSI, PYXS, ABUS, IRD side by side · Screen every company in Pharmaceutical Preparations ↗